Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes

Bioconjugate Chemistry

Volumn 23, Issue 9, 2012, Pages 1838-1855

  Barragán, Flavia ^a,b   Carrion Salip, Dolors ^c   Gómez Pinto, Irene ^d   González Cantó, Alejandro ^a,b   Sadler, Peter J ^e   De Llorens, Rafael ^c   Moreno, Virtudes ^b   González, Carlos ^d   Massaguer, Anna ^c   Marchán, Vicente ^a  

^a IBUB   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOTOXICITY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDES; PLATINUM COMPOUNDS; SYNTHESIS (CHEMICAL); TUMORS;

DIAMINOETHANE; DNA-BINDING; IMIDAZOL; OCTREOTIDE; P-CYMENE; PICOLINATES; SOLID PHASIS; SOLID-PHASE; SYNTHESISED; TUMOUR CELLS;

CELL CULTURE;

4 (1H IMIDAZOL YL)BENZOIC ACID; ANTINEOPLASTIC AGENT; LIGAND; METAL COMPLEX; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; [(N6 PARA CYM)RUTHENIUM CHLORIDE (IMIDAZOLE CO2H)(PPH3)];

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL STRAIN MCF 7; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN EXPRESSION; RECEPTOR BINDING; SOLID PHASE SYNTHESIS; TUMOR CELL;

EID: 84866353579     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300173h     Document Type: Article

References (70)

1. Reubi, J. C. (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr. Rev. 24, 389-427 (Pubitemid 37056239)
2. Zaccaro, L., del Gatto, A., Pedone, C., and Saviano, M. (2009) Peptides for tumour therapy and diagnosis: Current status and future directions Curr. Med. Chem. 16, 780-795
3. Okarvi, S. M. (2008) A comprehensive overview of peptide-based radiopharmaceuticals and cytotoxic conjugates, as well as their potential applications in cancer diagnosis and therapy Cancer Treat. Rev. 34, 13-26 (Pubitemid 351168607)
4. Mezo, G. and Manea, M. (2010) Receptor-mediated tumor targeting based on peptide hormones Expert Opin. Drug Delivery 7, 79-96
5. Schaer, J. C., Waser, B., Mengod, G., and Reubi, J. C. (1997) Somatostatin receptor subtype expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography Int. J. Cancer 70, 530-537 (Pubitemid 27149636)
6. Janecka, A., Zubrzycka, M., and Janecki, T. (2001) Somatostatin analogs J. Pept. Res. 58, 91-107 (Pubitemid 32738413)
7. Bauer, W., Briner, U., Dopfener, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., and Pless, J. (1982) SMS 201-995: a very potent and selective analogue of somatostatin with prolonged action Life Sci. 31, 1133-1140 (Pubitemid 13243115)
8. de Jong, M., Breeman, W. A. P., Kwekkeboom, D. J., Valkema, R., and Krenning, E. P. (2009) Tumor imaging and therapy using radiolabeled somatostatin analogues Acc. Chem. Res. 42, 873-880
9. Sun, L.-C. and Coy, D. H. (2008) Cytotoxic conjugates of peptide hormones for cancer chemotherapy Drugs Future 33, 217-223 (Pubitemid 351567920)
10. Wheate, N. J., Walker, S., Craig, G. E., and Oun, R. (2010) The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Trans. 39, 8113-8127
11. Jakupec, M. A., Galanski, M., Arion, V. B., Hartinger, C. G., and Keppler, B. K. (2008) Antitumour metal compounds: more than theme and variations Dalton Trans. 183-194 (Pubitemid 350278321)
12. van Rijt, S. H. and Sadler, P. J. (2009) Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs Drug Discovery Today 14, 1089-1097
13. Rademaker-Lakhai, J. M., Van den Bongard, D., Pluim, D., Beijnen, J. H., and Schellens, J. H. M. (2004) A phase I and pharmacological study with imidazolium- trans -DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent Clin. Cancer Res. 10, 3717-3727 (Pubitemid 38697605)
14. Jakupec, M. A., Arion, V. B., Kapitza, S., Reisner, E., Eichinger, A., Pongratz, M., Marian, B., Graf von Keyserlingk, N., and Keppler, B. K. (2005) KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development-an overview Int. J. Clin. Pharmacol. Ther. 43, 595-596 (Pubitemid 43009363)
15. Peacock, A. F. A. and Sadler, P. J. (2008) Medicinal organometallic chemistry: Designing metal arene complexes as anticancer agents Chem. Asian J. 3, 1890-1899
16. Levina, A., Mitra, A., and Lay, P. A. (2009) Recent developments in ruthenium anticancer drugs Metallomics 1, 458-470
17. Casini, A., Hartinger, C. G., Nazarov, A., and Dyson, P. J. (2010) Organometallic antitumour agents with alternative modes of action Top. Organomet. Chem. 32, 57-80
18. Gasser, G., Ott, I., and Metzler-Nolte, N. (2011) Organometallic anticancer compounds J. Med. Chem. 54, 3-25
19. Süss-Fink, G. (2010) Arene ruthenium complexes as anticancer agents Dalton Trans. 39, 1673-1688
20. Wang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., and Sadler, P. J. (2003) Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts Chem.-Eur. J. 9, 5810-5820
21. Kostrhunova, H., Florian, J., Novakova, O., Peacock, A. F. A., Sadler, P. J., and Brabec, V. (2008) DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media J. Med. Chem. 51, 3635-3643 (Pubitemid 351875019)
22. Pizarro, A. M., Habtemariam, A., and Sadler, P. J. (2010) Activation mechanisms for organometallic anticancer complexes Top. Organomet. Chem. 32, 21-56
23. Barragán, F., Moreno, V., and Marchán, V. (2009) Solid-phase synthesis and DNA binding studies of dichloroplatinum(II) conjugates of dicarba analogues of octreotide as new anticancer drugs Chem. Commun. 4705-4707
24. DAddona, D., Carotenuto, A., Novellino, E., Piccand, V., Reubi, J. C., Di Cianni, A., Gori, F., Papini, A. M., and Ginanneschi, M. (2008) Novel sst5-selective somatostatin dicarba-analogs: Synthesis and conformation-affinity relationships J. Med. Chem. 51, 512-520 (Pubitemid 351252279)
25. Barragán, F., López-Senín, P., Salassa, S., Betanzos-Lara, S., Habtemariam, A., Moreno, V., Sadler, P. J., and Marchán, V. (2011) Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex J. Am. Chem. Soc. 133, 14098-14108
26. Dirscherl, G. and König, B. (2008) The use of solid-phase synthesis techniques for the preparation of peptide-metal complex conjugates Eur. J. Org. Chem. 597-634
27. Metzler-Nolte, N. (2010) Biomedical applications of organometal-peptide conjugates Top. Organomet. Chem. 32, 195-217
28. Peindy NDongo, H. W., Ott, I., Gust, R., and Schatzschneider, U. (2009) Microwave-assisted solid-phase synthesis, cellular uptake, and cytotoxicity studies of cymantrene-peptide bioconjugates J. Organomet. Chem. 694, 823-827
29. Gross, A. and Metzler-Nolte, N. (2009) Synthesis and characterization of a ruthenocenoyl bioconjugate with the cyclic octapeptide octreotate J. Organomet. Chem. 694, 1185-1188
30. van Rijt, S. H., Kostrhunova, H., Brabec, V., and Sadler, P. J. (2011) Functionalization of osmium arene anticancer complexes with (Poly)arginine: effect on cellular uptake, internalization, and cytotoxicity Bioconjugate Chem. 22, 218-226
31. Puckett, C. A. and Barton, J. K. (2010) Targeting a ruthenium complex to the nucleus with short peptides Bioorg. Med. Chem. 18, 3564-3659
32. Splith, K., Hu, W., Schatzschneider, U., Gust, R., Ott, I., Onambele, L. A., Prokop, A., and Neundorf, I. (2010) Protease-activatable organometal-peptide bioconjugates with enhanced cytotoxicity on cancer cells Bioconjugate Chem. 21, 1288-1296
33. Mukhopadhyay, S., Barnes, C. M., Haskel, A., Short, S. M., Barnes, K. R., and Lippard, S. J. (2008) Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature Bioconjugate Chem. 19, 39-49 (Pubitemid 351213833)
34. Hsieh, H.-P., Wu, Y.-T., Chen, S.-T., and Wang, K.-T. (1999) Direct solid-phase synthesis of octreotide conjugates: precursors for use as tumor-targeted radiopharmaceuticals Bioorg. Med. Chem. 7, 1797-1803 (Pubitemid 29457676)
35. Moradell, S., Lorenzo, J., Rovira, A., Robillard, M. S., Aviles, F. X., Moreno, V., de Llorens, R., Martinez, M. A., Reedijk, J., and Llobet, A. (2003) Platinum complexes of diaminocarboxylic acids and their ethyl ester derivatives: the effect of the chelate ring size on antitumor activity and interactions with GMP and DNA J. Inorg. Biochem. 96, 493-502 (Pubitemid 37107462)
36. van Rijt, S. H., Peacock, A. F. A., Johnstone, R. D. L., Parsons, S., and Sadler, P. J. (2009) Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives Inorg. Chem. 48, 1753-1762
37. 2] at 203 K Polyhedron 23, 2695-2707
38. Chaplin, A. B. and Dyson, P. J. (2007) Catalytic activity of bis-phosphine ruthenium(II)-arene compounds: Structure-activity correlations Organometallics 26, 2447-2455 (Pubitemid 46733185)
39. Charvat, T. T., Lee, D. J., Robinson, W. E., and Chamberlin, A. R. (2006) Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase Bioorg. Med. Chem. 14, 4552-4567 (Pubitemid 43728677)
40. Gariepy, J., Remy, S., Zhang, X., Ballinger, J. R., Bolewska-Pedyczak, E., Rauth, M., and Bisland, K. (2002) A simple two-step approach for introducing a protected diaminedithiol chelator during solid-phase assembly of peptides Bioconjugate Chem. 13, 679-684 (Pubitemid 34527533)
41. Marchán, V., Moreno, V., Pedroso, E., and Grandas, A. (2001) Towards a better understanding of the cisplatin mode of action Chem.-Eur. J. 7, 808-815 (Pubitemid 32182649)
42. 2 cross-links Chem.-Eur. J. 10, 5369-5375
43. Algueró, B., López de la Osa, J., González, C., Pedroso, E., Marchán, V., and Grandas, A. (2006) Selective platination of modified oligonucleotides and duplex cross-links Angew. Chem., Int. Ed. 45, 8194-8197 (Pubitemid 44974161)
44. Goddard, D. T. and Kneller, G. SPARKY, University of California, San Francisco.
45. Singh, S. K., Trivedi, M., Chandra, M., Sahay, A. N., and Pandey, D. S. (2004) Luminescent piano-stool complexes incorporating 1-(4-cyanophenyl) imidazole: Synthesis, spectral, and sructural studies Inorg. Chem. 43, 8600-8608 (Pubitemid 40024172)
46. Koradi, R., Billeter, M., and Wuthrich, K. (1996) MOLMOL: a program for display and analysis of macromolecular structures J. Mol. Graphics 14, 29-32
47. Peacock, A. F. A., Parsons, S., and Sadler, P. J. (2007) Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O -chelating ligands to achieve cancer cell cytotoxicity J. Am. Chem. Soc. 129, 3348-3357 (Pubitemid 46449365)
48. van Rijt, S. H., Mukherjee, A., Pizarro, A. M., and Sadler, P. J. (2010) Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells J. Med. Chem. 53, 840-849
49. Morris, R. E., Aird, R. E., Murdoch, P., del, S., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., and Sadler, P. J. (2001) Inhibition of cancer cell growth by ruthenium(II) arene complexes J. Med. Chem. 44, 3616-3621 (Pubitemid 33026669)
50. Moreno, V., Font-Bardia, M., Calvet, T., Lorenzo, J., Aviles, F. X., Garcia, M. H., Morais, T. S., Valente, A., and Robalo, M. P. (2011) DNA interaction and cytotoxicity studies of new ruthenium(II) cyclopentadienyl derivative complexes containing heteroaromatic ligands J. Inorg. Biochem. 105, 241-249
51. Gianferrara, T., Bratsos, I., and Alessio, E. (2009) A categorization of metal anticancer compounds based on their mode of action Dalton Trans. 37, 7588-7598
52. Jennerwein, M. and Andrews, P. A. (1995) Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II) Drug Metab. Dispos. 23, 178-184
53. Wang, F., Habtemariam, A., van der Geer, E. P. L., Fernandez, R., Melchart, M., Deeth, R. J., Aird, R., Guichard, S., Fabbiani, F. P. A., Lozano-Casal, P., Oswald, I. D. H., Jodrell, D. I., Parsons, S., and Sadler, P. J. (2005) Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity Proc. Natl. Acad. Sci. U.S.A. 102, 18269-18274 (Pubitemid 43011216)
54. Peacock, A. F. A., Habtemariam, A., Moggach, S. A., Prescimone, A., Parsons, S., and Sadler, P. J. (2007) Chloro half-sandwich osmium(II) complexes: influence of chelated N,N -ligands on hydrolysis, guanine binding, and cytotoxicity Inorg. Chem. 46, 4049-4059
55. Novakova, O., Chen, H., Vrana, O., Rodger, A., Sadler, P. J., and Brabec, V. (2003) DNA Interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media Biochemistry 42, 11544-11554 (Pubitemid 37205749)
56. Liu, H.-K., Wang, F., Parkinson, J. A., Bella, J., and Sadler, P. J. (2006) Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes Chem.-Eur. J. 12, 6151-6165 (Pubitemid 44231037)
57. Gossens, C., Tavernelli, I., and Rothlisberger, U. (2009) Binding of organometallic ruthenium(II) anticancer compounds to nucleobases: A computational study J. Phys. Chem. A 113, 11888-11897
58. Kostrhunova, H., Florian, J., Novakova, O., Peacock, A. F. A., Sadler, P. J., and Brabec, V. (2008) DNA Interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media J. Med. Chem. 51, 3635-3643 (Pubitemid 351875019)
59. Fischer, R., Mader, O., Jung, G., and Brock, R. (2003) Extending the applicability of carboxyfluorescein in solid-phase synthesis Bioconjugate Chem. 14, 653-660 (Pubitemid 36597377)
60. Watson, J. C., Balster, D. A., Gebhardt, B. M., ODorisio, T. M., ODorisio, M. S., Espenan, G. D., Drouant, G. J., and Woltering, E. A. (2001) Growing vascular endothelial cells express somatostatin subtype 2 receptors Br. J. Cancer 85, 266-272 (Pubitemid 32695750)
61. Hornick, C. A., Anthony, C. T., Hughey, S., Gebhardt, B. M., Espenan, G. D., and Woltering, E. A. (2000) Progressive nuclear translocation of somatostatin analogs J. Nucl. Med. 41, 1256-1263 (Pubitemid 30464012)
62. Zhang, Y., Wang, X., Wang, J., Zhang, X., and Zhang, Q. (2011) Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells Pharm. Res. 28, 1167-1178
63. Huang, C. M., Wu, Y. T., and Chen, S. T. (2000) Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis Chem. Biol. 7, 453-461
64. Wynants, C., Van Binst, G., and Loosli, H. R. (1985) SMS 201-995, a very potent analogue of somatostatin. Assignment of the 1H 500 MHz n.m.r. spectra and conformational analysis in aqueous solution Int. J. Pept. Protein Res. 25, 608-614 (Pubitemid 15041508)
65. Wynants, C., Van Binst, G., and Loosli, H. R. (1985) SMS 201-995, an octapeptide somatostatin analogue. Assignment of the 1H 500 MHz n.m.r. spectra and conformational analysis of SMS 201-995 in dimethylsulfoxide Int. J. Pept. Protein Res. 25, 615-621 (Pubitemid 15041509)
66. Melacini, G., Zhu, Q., and Goodman, M. (1997) Multiconformational NMR Analysis of sandostatin (octreotide): equilibrium between β-sheet and helical structures Biochemistry 36, 1233-1241 (Pubitemid 27074947)
67. Deshmukh, M. V., Voll, G., Kuehlewein, A., Maecke, H., Schmitt, J., Kessler, H., and Gemmecker, G. (2005) NMR studies reveal structural differences between the Gallium and Ytrium complexes of DOTA-D-Phe1-Tyr3-octreotide J. Med. Chem. 48, 1506-1514 (Pubitemid 40364558)
68. Reubi, J. C., Schar, J. C., Waser, B., Wenger, S., Heppeter, A., Schmitt, J. S., and Mäcke, H. R. (2000) Affinity profiles for human somatostatin receptor subtypes sstr1-sstr5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur. J. Nucl. Med. 27, 273-282 (Pubitemid 30167697)
69. Zhang, J., Jin, W., Wang, X., Wang, J., Zhang, X., and Zhang, Q. (2010) A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models Mol. Pharm. 7, 1159-1168
70. Cascini, G. L., Cuccurullo, V., and Mansi, L. (2010) The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology Q. J. Nucl. Med. Mol. Imaging 54, 24-36